Ultrasound contrast agent Optison has been cleared for sale in the European Union. Amersham Health will begin marketing the echocardiography agent this month. The company obtained comarketing rights to the product from Mallinckrodt in
Ultrasound contrast agent Optison has been cleared for sale in the European Union. Amersham Health will begin marketing the echocardiography agent this month. The company obtained comarketing rights to the product from Mallinckrodt in 2000.
Could Virtual Non-Contrast Images from Photon-Counting CT Reduce Radiation Dosing with CCTA?
March 28th 2024Emerging research on coronary artery calcium scoring for the assessment of coronary artery disease (CAD) suggests the use of virtual non-contrast images from photon-counting CT may lead to a nearly 20 percent reduction in radiation dosing.
FDA Clears CT-Based AI Tools for PE Detection and Stroke Severity Assessment
March 26th 2024The artificial intelligence (AI) modalities CINA-iPE and CINA-ASPECTS may facilitate improved detection of incidental pulmonary embolism and stroke evaluation, respectively, based on computed tomography (CT) scans.